**Question:** Which of the following drugs acts on trabecular mesh-work and affects the aqueous outflow?

A. Timolol
B. Diclofenac
C. Amlodipine
D. Simvastatin

**Core Concept:**
The trabecular meshwork (TM) is a part of the eye's aqueous humor outflow pathway, which is responsible for regulating the pressure inside the eye (intraocular pressure, IOP). Adequate outflow of aqueous humor is crucial to maintain eye health and vision.

**Why the Correct Answer is Right:**
The correct answer, Timolol, is a non-selective beta-blocker that acts on the trabecular meshwork. By blocking beta receptors, it reduces the production of prostaglandins, which are involved in the regulation of aqueous humor outflow. Consequently, the IOP decreases.

**Why Each Wrong Option is Incorrect:**

A. Diclofenac: A nonsteroidal anti-inflammatory drug (NSAID), diclofenac primarily acts on the cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. While it can affect IOP indirectly by reducing prostaglandin production, its primary action is on inflammation rather than aqueous humor outflow.

B. Amlodipine: A calcium channel blocker, amlodipine targets vascular smooth muscle relaxation to improve blood flow and reduce IOP. However, its primary action is on blood vessels rather than the trabecular meshwork and aqueous humor outflow.

C. Amlodipine (repeated): As mentioned above, amlodipine primarily targets vascular smooth muscle relaxation, not aqueous humor outflow.

**Clinical Pearl:**

Selective beta-blockers like Timolol are more specific in affecting the aqueous humor outflow and are commonly used medications to reduce IOP in glaucoma patients. Non-selective beta-blockers like Amlodipine primarily target blood vessels, and NSAIDs like Diclofenac indirectly affect IOP by reducing prostaglandin production.

**Correct Answer Explanation:**
Timolol is a selective beta-blocker, meaning it specifically targets beta receptors located in the trabecular meshwork and reduces prostaglandin synthesis, leading to improved aqueous humor outflow and a decrease in intraocular pressure. This makes Timolol an appropriate medication for managing glaucoma and other conditions associated with elevated IOP. Timolol is a beta-blocker that competes with propranolol for binding to beta receptors, but has a higher affinity for beta-1 receptors in the trabecular meshwork, allowing it to reduce aqueous humor production and improve outflow.

**Why Diclofenac is Wrong:**
Diclofenac is an NSAID (nonsteroidal anti-inflammatory drug) that primarily acts as an inhibitor of cyclooxygenase (COX) enzymes, which are involved in prostaglandin synthesis. By blocking COX enzymes, Diclofenac indirectly affects intraocular pressure by decreasing prostaglandin production, but its primary mechanism is